KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Treasury Shares (2016 - 2025)

Jazz Pharmaceuticals has reported Treasury Shares over the past 14 years, most recently at $789000.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $789000.0 for Q4 2025, up 1.02% from a year ago — trailing twelve months through Dec 2025 was $789000.0 (up 1.02% YoY), and the annual figure for FY2025 was $789000.0, up 1.02%.
  • Treasury Shares for Q4 2025 was $789000.0 at Jazz Pharmaceuticals, up from $781000.0 in the prior quarter.
  • Over the last five years, Treasury Shares for JAZZ hit a ceiling of $3.6 million in Q4 2023 and a floor of $214000.0 in Q4 2021.
  • Median Treasury Shares over the past 5 years was $800000.0 (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Treasury Shares: crashed 82.17% in 2021 and later soared 709.77% in 2023.
  • Jazz Pharmaceuticals' Treasury Shares stood at $214000.0 in 2021, then soared by 105.61% to $440000.0 in 2022, then soared by 709.77% to $3.6 million in 2023, then tumbled by 78.08% to $781000.0 in 2024, then grew by 1.02% to $789000.0 in 2025.
  • The last three reported values for Treasury Shares were $789000.0 (Q4 2025), $781000.0 (Q4 2024), and $2.8 million (Q3 2024) per Business Quant data.